Movement Alert｜RemeGen Rises 5.68% in Regular Trading, Core Product Telitacicept Receives Approval for Two New Indications

Market Focus06-09 10:25

On June 9, RemeGen rose 5.68% in regular trading, trading at 72.35 HKD/share, with trading volume of HKD 236 million. The rally was driven by the announcement that its core product Telitacicept received marketing approval for two new indications.

According to the company disclosure, injectable Telitacicept was approved for the treatment of Sjogren's syndrome, while Telitacicept injection for IgA nephropathy received conditional approval via priority review. Telitacicept is the world's first BLyS/APRIL dual-target innovative biologic, simultaneously inhibiting BLyS and APRIL binding to B-cell surface receptors to block abnormal B-cell differentiation and maturation. The Sjogren's syndrome Phase III trial represents the first dual-target biologic globally to achieve strongly positive results in this indication, while IgA nephropathy Phase III data has been published in The New England Journal of Medicine, underscoring its clinical significance.

Within the Biotechnology sector, performance was mixed. Among peers, AKESO down 0.05%, INNOVENT BIO up 0.96%, BEIGENE down 1.04%, SKB BIO up 4.14%, 3SBIO up 4.01%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1144403937?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-09 10:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144403937","market":"us","top_or_hot":-1,"title":"Movement Alert｜RemeGen Rises 5.68% in Regular Trading, Core Product Telitacicept Receives Approval for Two New Indications","media":"Market Focus","content":"<p><p>On June 9, RemeGen rose 5.68% in regular trading, trading at 72.35 HKD/share, with trading volume of HKD 236 million. The rally was driven by the announcement that its core product Telitacicept received marketing approval for two new indications.</p><p>According to the company disclosure, injectable Telitacicept was approved for the treatment of Sjogren's syndrome, while Telitacicept injection for IgA nephropathy received conditional approval via priority review. Telitacicept is the world's first BLyS/APRIL dual-target innovative biologic, simultaneously inhibiting BLyS and APRIL binding to B-cell surface receptors to block abnormal B-cell differentiation and maturation. The Sjogren's syndrome Phase III trial represents the first dual-target biologic globally to achieve strongly positive results in this indication, while IgA nephropathy Phase III data has been published in The New England Journal of Medicine, underscoring its clinical significance.</p><p>Within the Biotechnology sector, performance was mixed. Among peers, AKESO down 0.05%, INNOVENT BIO up 0.96%, BEIGENE down 1.04%, SKB BIO up 4.14%, 3SBIO up 4.01%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜RemeGen Rises 5.68% in Regular Trading, Core Product Telitacicept Receives Approval for Two New Indications</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜RemeGen Rises 5.68% in Regular Trading, Core Product Telitacicept Receives Approval for Two New Indications\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-09 10:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 9, RemeGen rose 5.68% in regular trading, trading at 72.35 HKD/share, with trading volume of HKD 236 million. The rally was driven by the announcement that its core product Telitacicept received marketing approval for two new indications.</p><p>According to the company disclosure, injectable Telitacicept was approved for the treatment of Sjogren's syndrome, while Telitacicept injection for IgA nephropathy received conditional approval via priority review. Telitacicept is the world's first BLyS/APRIL dual-target innovative biologic, simultaneously inhibiting BLyS and APRIL binding to B-cell surface receptors to block abnormal B-cell differentiation and maturation. The Sjogren's syndrome Phase III trial represents the first dual-target biologic globally to achieve strongly positive results in this indication, while IgA nephropathy Phase III data has been published in The New England Journal of Medicine, underscoring its clinical significance.</p><p>Within the Biotechnology sector, performance was mixed. Among peers, AKESO down 0.05%, INNOVENT BIO up 0.96%, BEIGENE down 1.04%, SKB BIO up 4.14%, 3SBIO up 4.01%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1144403937","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144403937","pubTimestamp":1780971926,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 9, RemeGen rose 5.68% in regular trading, trading at 72.35 HKD/share, with trading volume of HKD 236 million. The rally was driven by the announcement that its core product Telitacicept...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"动静快讯|RemeGen常规交易涨5.68%核心产品Telitacicept两项新适应症获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"On June 9, RemeGen rose 5.68% in regular trading, trading at 72.35 HKD/share, with trading volume of HKD 236 million. The rally was driven by the announcement that its core product Telitacicept received marketing approval for two new indications.According to the company disclosure, injectable Telitacicept was approved for the treatment of Sjogren's syndrome, while Telitacicept injection for IgA nephropathy received conditional approval via priority review. Telitacicept is the world's first BLyS/APRIL dual-target innovative biologic, simultaneously inhibiting BLyS and APRIL binding to B-cell surface receptors to block abnormal B-cell differentiation and maturation. The Sjogren's syndrome Phase III trial represents the first dual-target biologic globally to achieve strongly positive results in this indication, while IgA nephropathy Phase III data has been published in The New England Journal of Medicine, underscoring its clinical significance.Within the Biotechnology sector, performance was mixed. Among peers, AKESO down 0.05%, INNOVENT BIO up 0.96%, BEIGENE down 1.04%, SKB BIO up 4.14%, 3SBIO up 4.01%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1144403937","isCrawlerRequest":true}